e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
Prevalences and characterstics of obstructive airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
COPD subtypes most likely to benefit from inhaled corticosteroids (ICS): Cluster analysis
R. DiSantostefano, H. Li, D. Rubin, D. Stempel (Research Triangle Park, United States Of America)
Source:
Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Session:
Prevalences and characterstics of obstructive airway disease
Session type:
Poster Discussion
Number:
4753
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. DiSantostefano, H. Li, D. Rubin, D. Stempel (Research Triangle Park, United States Of America). COPD subtypes most likely to benefit from inhaled corticosteroids (ICS): Cluster analysis. Eur Respir J 2012; 40: Suppl. 56, 4753
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA)
versus
similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Is the combination of long-acting β
2
-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Efficacy of an inhaled corticosteroid/long-acting ?2-agonist combination in symptomatic COPD patients in GOLD groups B and D
Source: Eur Respir J 2015; 46: 255-258
Year: 2015
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
ERS guideline on withdrawal of inhaled corticosteroids in COPD
Source: ERS webinar 2021: ERS guideline on withdrawal of inhaled corticosteroids in COPD
Year: 2021
Meta-analysis of inhaled corticosteroids response in children with asthma.
Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept